10-Q: Yubo International Biotech Reports Q1 2024 Results with Revenue Decline and Increased Operating Expenses

Yubo International Biotech's Q1 2024 results show a significant decrease in revenue and an increase in operating expenses, leading to a larger net loss compared to the same period last year.

Summary

• Yubo International Biotech reported a decrease in revenue to $3,488 for the first quarter of 2024, down from $156,615 in the same period of 2023, primarily due to reduced sales of oral liquid health products.
• The cost of goods sold also decreased to $827 from $98,925 year-over-year, reflecting the lower sales volume.
• Gross profit decreased significantly to $2,661 in Q1 2024 from $57,690 in Q1 2023.
• Operating expenses increased to $412,082 in Q1 2024 from $374,222 in Q1 2023, driven by higher depreciation and amortization of property and equipment, and increased occupancy expenses.
• The company's loss from operations widened to $409,421 in Q1 2024 compared to $316,532 in Q1 2023.
• Net loss for the quarter was $409,505, compared to a net loss of $316,667 in the same quarter of the previous year.
• The company had cash and equivalents of $57,024 and a negative working capital of $2,783,704 as of March 31, 2024.
• The company's ability to continue as a going concern is dependent on generating profitable operations or obtaining necessary financing.

Sentiment

Score: 2

Explanation: The document presents a very negative financial picture with significant revenue decline, increased losses, and a going concern warning. The company's reliance on a single customer and low cash position further contribute to the negative sentiment.

Positives

• Cost of goods sold decreased to $827 in Q1 2024 from $98,925 in Q1 2023, reflecting lower sales volume.
• The company received a capital contribution of $97,979 to its subsidiary Yubo Shenzhen from a non-controlling interest.

Negatives

• The company experienced a significant decrease in revenue, primarily due to reduced sales of oral liquid health products.
• The company's operating expenses increased, driven by higher depreciation and amortization, and increased occupancy expenses.
• The company's net loss increased due to decreased gross profit and increased operating expenses.
• The company has a negative working capital of $2,783,704.
• The company's cash position is very low at $57,024.
• The company's financial statements include an explanatory note referring to recurring operating losses and expressing substantial doubt in the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on generating profitable operations or obtaining necessary financing.
• The company faces risks related to its VIE structure, including potential non-compliance with PRC laws and regulations.
• The company may be subject to penalties or forced to relinquish its interests in Yubo Beijing if the PRC government finds its agreements non-compliant.
• The company is subject to the Holding Foreign Companies Accountable Act, which could lead to delisting if the PCAOB cannot inspect its auditor.
• The company may be subject to cybersecurity reviews and data privacy regulations in China, which could disrupt operations and increase costs.
• The company relies on a limited number of customers for a significant portion of its revenue, creating customer concentration risk.
• The company may face difficulties in obtaining additional financing, which could lead to scaling back or eliminating operations.

Future Outlook

The company intends to continue working toward identifying and obtaining new sources of financing and intends to raise additional capital in the second half of 2024 through the next fiscal year. No assurances can be given that the company will be successful in obtaining additional financing in the future.

Management Comments

• Management plans to obtain capital from management and significant shareholders to meet minimal operating expenses.
• Management is seeking third-party equity and/or debt financing.

Industry Context

The company operates in the biotechnology sector, which is characterized by high research and development costs, regulatory hurdles, and the need for significant capital investment. The company's focus on stem cell technology places it in a niche market with potential for growth but also significant risks.

Comparison to Industry Standards

• The company's revenue decline and increased losses are concerning when compared to industry standards for biotech companies, which often require significant revenue growth to offset high operating costs.
• Many comparable biotech companies are focused on specific therapeutic areas and have a clear path to regulatory approval, while Yubo Beijing's focus on endometrial stem cells is less common and may face unique regulatory challenges.
• Companies like CRISPR Therapeutics and Editas Medicine, which are also in the gene editing and cell therapy space, have significantly higher market capitalizations and more established revenue streams, although they also face similar challenges in terms of regulatory approvals and commercialization.
• The company's reliance on a single customer for a large portion of its revenue is not typical for established biotech companies, which usually have a more diversified customer base.
• The company's negative working capital and low cash position are also concerning when compared to industry benchmarks, as most biotech companies require substantial capital to fund research and development.

Related Party Transactions

• The company has payables due to related parties, including Mr. Jun Wang, Mr. Yang Wang, Ms. Huang Li, and Mr. Jin Wei.
• On February 27, 2020, Yubo Beijing executed an Entrustment Technical Service Agreement with Beijing Zhenhuikang Biotechnology Co. LTD (Zhenhuikang), an entity controlled by Mr. Yulin Cao.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures or operational changes.
• Customers may be affected by potential disruptions in product availability or service quality.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to continue working toward identifying and obtaining new sources of financing.
• The company intends to raise additional capital in the second half of 2024 through the next fiscal year.

Key Dates

Keywords

Biotech, Stem Cell, Financial Results, Revenue Decline, Operating Expenses, Net Loss, Going Concern, China Operations, VIE Structure, Regulatory Risks